Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Madrigal PharmaceuticalsMDGL +0.26%31 Cash-to-Debt is 2.41 as of Jun. 2026, which is 99% below its 10-year median of 336.35. GuruFocus rates MDGL with a GF Score™ of 31/100. The stock has 4 warning signs investors should review. Among 1,396 Biotechnology companies, Madrigal Pharmaceuticals ranks worse than 64.9% on this metric.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Madrigal Pharmaceuticals's cash to debt ratio for the quarter that ended in Jun. 2026 was 2.41.
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Madrigal Pharmaceuticalscould pay off its debt using the cash in hand for the quarter that ended in Jun. 2026.
The historical rank and industry rank for Madrigal Pharmaceuticals's Cash-to-Debt or its related term are showing as below:
MDGL'
s Cash-to-Debt Range Over the Past 10 Years
Min: 1.99 Med: 336.35 Max: No Debt
Current: 2.41
During the past 13 years, Madrigal Pharmaceuticals's highest Cash to Debt Ratio was No Debt. The lowest was 1.99. And the median was 336.35.
MDGL's Cash-to-Debt is ranked worse than 64.9% of 1396
companies
in the Biotechnology industry
Industry Median: 7.175
vs MDGL: 2.41
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
Madrigal Pharmaceuticals Cash-to-Debt Related Terms
Madrigal Pharmaceuticals Cash-to-Debt Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
For the Biotechnology subindustry, Madrigal Pharmaceuticals's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Madrigal Pharmaceuticals Cash-to-Debt vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Madrigal Pharmaceuticals's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where Madrigal Pharmaceuticals's Cash-to-Debt falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Madrigal Pharmaceuticals (MDGL) has a Cash-to-Debt of 2.41 as of Jun. 2026. This is 99% below median its historical median of 336.35. Over the past decade, Madrigal Pharmaceuticals' Cash-to-Debt has ranged from 1.99 to 10,000.00. According to the industry distribution chart, Madrigal Pharmaceuticals ranks #906 out of 1396 companies in the Biotechnology industry, placing it in the top 64.9%.
Is Madrigal Pharmaceuticals' Cash-to-Debt too high?
Madrigal Pharmaceuticals' current Cash-to-Debt of 2.41 is 99% below median its 10-year median of 336.35. Over the past 10 years, this metric has ranged from a low of 1.99 to a high of 10,000.00. The Biotechnology industry median Cash-to-Debt is 7.18. Madrigal Pharmaceuticals' value of 2.41 is 66.4% below this industry median. Based on the distribution chart, Madrigal Pharmaceuticals ranks #906 out of 1396 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Madrigal Pharmaceuticals has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Madrigal Pharmaceuticals' Cash-to-Debt compare to CORT and BMRN?
According to the Biotechnology industry distribution chart, Madrigal Pharmaceuticals ranks #906 out of 1396 companies for Cash-to-Debt. This places Madrigal Pharmaceuticals in the lower half of its industry. The industry median Cash-to-Debt is 7.18. Madrigal Pharmaceuticals' value of 2.41 is 66.4% below this benchmark. Historically, Madrigal Pharmaceuticals' own Cash-to-Debt has ranged from 1.99 to 10,000.00 over the past decade. While the company's 10-year median is 336.35 vs. the industry median of 7.18, Madrigal Pharmaceuticals has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Biotechnology company?
The median Cash-to-Debt among Biotechnology companies is 7.18, based on 1,396 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Madrigal Pharmaceuticals's current Cash-to-Debt of 2.41 is 66.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Cash-to-Debt is 7.18 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Madrigal Pharmaceuticals's current Cash-to-Debt is 2.41, which is 99% below median its own 10-year median of 336.35. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Madrigal Pharmaceuticals stock overvalued right now?
Madrigal Pharmaceuticals (MDGL) has a current Cash-to-Debt of 2.41. The current Cash-to-Debt is 2.41, which is 99% below median its 10-year median of 336.35 and 66.4% below the Biotechnology industry median of 7.18. Madrigal Pharmaceuticals' overall GF Score™ is 31/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For Madrigal Pharmaceuticals (MDGL), the current Cash-to-Debt is 2.41 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, liver cancer, need for liver transplantation and premature mortality. Its medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor beta agonist designed to target key underlying causes of MASH.
31GF Score
Get the complete analysis for MDGL
Cash-to-Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MDGL has been successfully added to your 
